Lung Therapeutics Announces Successful Completion of Phase Ia Clinical Trial of LTI-03 in Healthy Volunteers

By
Justin.choi
-
0
119
Lung Therapeutics, Inc. announced the successful completion of a Phase Ia clinical trial for LTI-03, a Caveolin-1-related peptide designed to treat idiopathic pulmonary fibrosis.
[Lung Therapeutics, Inc]

Sorry, but the selected Zotpress account can't be found.

Press Release